US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-21 20:37:57 Source:businessViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
You may also like
- Strictly star Giovanni Pernice's former partner Rose Ayling
- Shanghai citizens average 12 books per year
- Three signs Princess Charlotte's birthday portrait, taken by Kate Middleton, was not retouched
- Mississippi high court declines to rule on questions of public funds going to private schools
- Ohio judge to rule Monday on whether the state’s abortion ban stands
- Some Houston
- Kentucky judge declines, for now, to lift ban on executions
- Fashion show boosts China
- Sports betting roundup: Xander Schauffele's final putt pays off for bettors